Pharmacovigilance identifies antidiabetic drugs, including GLP-1 agonists, as Inflammatory Bowel Disease repurposing candidates.
Prioritizing Antidiabetic Drugs for Inflammatory Bowel Disease Through Inverse Signal Detection: A FAERS Pharmacovigilance Study
Abstract
A pharmacovigilance study using FAERS data identified antidiabetic drugs, such as GLP-1 receptor agonists, as potential repurposing candidates for Inflammatory Bowel Disease by detecting inverse signals.